The mechanisms responsible for garlic - Drug interactions and their in vivo relevance

Current Drug Metabolism

Volumn 14, Issue 1, 2013, Pages 90-101

  Berginc, Katja ^a   Kristl, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

CYP3A4; Flavonoids; Garlic supplement; Permeability; Pharmacokinetic interactions; Sulfur containing compounds; Transporters

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GARLIC EXTRACT; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 1; PEPTIDE TRANSPORTER 1; RITONAVIR; SAQUINAVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CELL LINE; CELL VIABILITY; DRUG MECHANISM; ELECTROPHYSIOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MALE; NONHUMAN; PHYTOCHEMISTRY; RAT;

EID: 84871303484     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920013804545188     Document Type: Article

References (62)

1. Bruno, J. J.; Ellis, J. J. Herbal use among US elderly: 2002 national health interview survey. Ann. Pharmacother., 2005, 39, 643-648.
2. Maughan, R. J.; King, D. S.; Trevor, L. Dietary Supplements. J. Sport Sci., 2004, 22, 95-113.
3. Supplement business report. Nutr. Business J. 1, 2009.
4. Foster, B. C.; Arnason, J. T.; Briggs, C. In: Herbal medicines; Barnes, J.; Anderson L. A.; Phillipson J. D., Ed.; Pharmaceutical Press, 2007, 3rd ed.; pp. 279-289.
5. Venkataramanan, R.; Komorski, B.; Strom, S. In vitro and in vivo assessment of herb drug interactions. Life Sci., 2006, 78, 2105-2115.
6. Lila, M. A.; Raskin, I. Health-related interactions of phytochemicals. J. Food Sci., 2006, 70, R20-R27.
7. Hu, Z.; Yang, X.; Ho, P. C. L.; Chan, S. Y.; Heng P. W. S.; Chan, E.; Duan, W.; Koh, H. L.; Zhou, S. Herb-drug interactions, a literature review. Drugs, 2005, 65, 1239-1282.
8. Zhou, S.; Gao, Y.; Jiang, W.; Huang, M.; Xu, A.; Paxton, J. W. Interactions of herbs with Cytochrome P450. Drug Metab. Rev., 2003, 35, 35-98.
9. Borrelli, F.; Capasso, R.; Izzo, A. A. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Mol. Nutr. Food Res., 2007, 51, 1386-1397.
10. Banerjee, S.; Maulik, S. K. Effects of garlic on cardiovascular disorders: a review. Nutrition J., 2002, 1, 4-18.
11. Williamson E. M. Drug interactions between herbal and prescription medicines. Drug Safety, 2003, 26, 1075-1092.
12. Mills, E.; Montori, V.; Perri, D.; Phillips, E.; Koren, G. Natural health-HIV drug interactions: a systematic overview. Int. J. STD&AIDS, 2005, 16, 181-186.
13. Fugh-Bergman, A.; Ernst E. Herb-drug interactions: review and assessment of report reliability. Br. J. Clin. Pharmacol, 2001, 52, 587-595.
14. Piscitelli, S. C.; Burstein, A. H.; Welden N.; Gallicano K. D.; Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis., 2002, 34, 234-238.
15. Gallicano, K.; Foster, B.; Choudhri, S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmacol, 2002, 55, 199-202.
16. Amagase, H. Clarifying the real bioactive constituents of garlic. J. Nutr., 2006, 136, 716S-725S.
17. Lawson, L. D.; Wang, Z. J. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. J. Agric. Food Chem., 2001, 49, 2592-2599.
18. Yeh, Y. Y.; Liu, L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J. Nutr., 2001, 131, 989S-993S.
19. Hinchman, C. A.; Matsumoto, H.; Simmons, T. W.; Ballatori, N. Intrahepatic conversion of glutathione conjugates to its mercapturic acid. J. Biol. Chem., 1991, 166, 22179-22185.
20. Lancaster, J. E.; Boland, M. J. Flavor biochemistry. In: Brewster JL, Rabinowitch HD (ed) Onions and allied crops, Food science and Minor crops, CRC Press, USA, 1989, 34-54.
21. Jones, M. G.; Hughes, J.; Tregova, A.; Milne J, Tomsett, A. B.; Collin, H. A. Biosynthesis of the flavour precursors of onion and garlic. J. Exp. Bot, 2004, 55, 1903-1918
22. Berginc, K.; Zakelj, S.; Ursic, D.; Kristl, A. Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol. Pharm. Bull, 2009, 32, 694-699.
23. Ejaz, S.; Woong, L. C.; Ejaz, A. Extract of garlic (Allium Sativum) in cancer chemoprevention. Exp. Oncol, 2004, 25, 93-97.
24. Milisav, I.; Nipic, D.; Suput, D. The riddle of mitochondrial caspase-3 from liver. Apoptosis, 2009, 14, 1070-1075.
25. Berginc, K.; Zakelj, S.; Kristl, A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur. J. Nutr., 2010, 49, 373-384.
26. Berginc, K.; Trdan, T.; Trontelj, J.; Kristl, A. HIV-protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Accepted in Biopharm. Drug Dispos., 2010.
27. Berginc, K.; Milisav, I.; Kristl, A. Garlic flavonoids and organosulfur compounds: the impact on saquinavir and darunavir hepatic metabolism and distribution. Accepted in Drug Metab. Pharmacokinet., 2011.
28. Idriss, H. T.; Hannun, Y. A.; Boulpaep, E.; Basavappa, S. Regulation of volume-activated chloride channely by P-glycoprotein: phosphorylation has the final say!. J. Physiol, 2000, 524(3), 629-636.
29. Macpherson, L. J.; Geierstanger, B. H.; Viswanath, V.; Bandell, M.; Eid, S. R.; Hwang, S. W.; Patapoutian, A. The Pungency of Garlic: Activation of TRPA1 and TRPV1 in Response to Allicin. Curr. Biol, 2005, 15, 929-934.
30. Siegel, G.; Nuck, R.; Schanlke, F.; Michel, F. Molecular evidence of pharmacological K+ channel opening by garlic in human vascular smooth muscle cell membranes. Phytother. Res., 1998, 12, S149-S151.
31. Lewis, S. A. In: Epithelial transport. Wills, N. K.; Reuss, L.; Lewis, S. A., Ed.; Chapman & Hall: London Weinheim New York Tokyo Melbourne Madras, 1996;1st ed.; pp 93-117.
32. Liedtke, W. B. In: TRP ion channel function in sensory transduction and cellular signaling cascades. Liedtke, W. B.; Heller, S., Ed.; Boca Raton, Fla: CRC/Taylor & Francis, 2007; Frontiers in neuroscience, pp 303-318.
33. Bautista, D. M.; Movahed, P.; Hinman, A.; Axelsson, H. E.; Sterner, O.; Högestätt, E. D.; Julius, D.; Jordt, S. E.; Zygmunt, P. M. Pungent products from garlic activate the sensory ion channel TRPA1. PNAS, 2005, 102, 12248-12252.
34. McNamara, F. N.; Randall, A.; Gunthorpe, M. J. Effects of piperine, the pungent component of black peppet, at the human vanniloid receptor (TRP-V1). Brit. J. Pharmacol, 2005, 144, 781-790.
35. Hwang, T. C.; Sheppard, D. N. Molecular pharmacology of the CFTR Cl-channel. Trends Pharmacol. Sci., 1999, 20, 448-453.
36. Berginc, K.; Trontelj, J.; Kristl, A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab. Pharmacokinet, 2010, 25, 307-313.
37. Berginc, K.; Kristl, A. Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug and drug-food interactions. Accepted in J. Med. Food, 2011, 14, 1-5.
38. Chan, L. M. S.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting absorption and bioavailability. Eur. J. Pharm. Sci., 2004, 21, 25-51.
39. Gerk, P. M.; Vore, M. Regulation of expression of the multiple resistance-associated protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther., 2002, 302, 407-415.
40. Nakanishi, T.; Doyle, L. A.; Hassel, B.; Wei, Y.; Bauer, K. S.; Wu, S.; Pumplin, D. W.; Fang, H. B.; Ross, D. D. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol, 2003, 64, 1452-1462.
41. Martin, C; Berridge, G.; Higgins, C. F.; Mistery, P.; Charlton, P.; Callaghan, R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol, 2000, 58, 624-632.
42. Zhou, S.; Lim, L. Y.; Chowbay, B. Herbal modulation of P-glycoprotein. Drug Metab. Rev., 2004, 36, 57-104.
43. Petzinger, E.; Geyer, J. Drug transporters in pharmacokinetics. Naunyn-Schmiedeberg's Arch. Pharmacol, 2006, 372, 465-475.
44. Yang, C. Y.; Dantzig, A. H.; Pidgeon, C. Intestinal peptide transport system and oral drug availability. Pharm. Res., 1999, 16, 1331-1343.
45. Enerson, B. E., Drewes, L. R. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. Minireview. J. Pharm. Sci., 2003, 92, 1531-1544.
46. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J. I.; Tsuji, A.; Tamai, I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther., 2003, 306, 703-708.
47. Walter, E.; Kissel, T.; Amidon, G. L. The intestinal peptide carrier: a potential transport for small peptide derived drugs. Adv. Drug Deliver. Rev., 1996, 20, 33-58.
48. Gill, R. K.; Saksena, S.; Alrefai, W. A.; Sarwar, Z.; Goldstein, J. L.; Carrol, R. E.; Ramaswamy, K.; Dudeja, P. K. Expression and membrane localization of MCT isoforms along the length of the human small intestine. Am. J. Physiol. Cell Physiol., 2005, 289, C846-C852.
49. Teyssier, C.; Guenot, L.; Suschetet, M.; Siess, M. H. Metabolism of diallyl disulfide by human liver microsomal cytochromed P-450 and flavin-containing monooxygenases. Drug Metab. Dispos., 1999, 27, 835-841.
50. Greenblatt, D. J.; Leigh-Pemberton, R. A.; Moltke, L. L. In vitro interactions of water-soluble garlic components with human cytochrome P450. J. Nutr., 2006, 136, 806S-809S.
51. Goole, J.; Lindley, D. J.; Roth, W.; Carl, S. M., Amighi, K.; Kauffmann, J. M.; Knipp, G. T. The effects of excipients on transporter mediated absorption. Int. J. Pharm., 2010, 393, 17-31.
52. Amagase, H.; Petesch, B. L.; Matsuura, H.; Kasuga, S. Intake of garlic and its bioactive compounds. J. Nutr., 2001, 131, 955S-962S.
53. Coecke, S.; Rogiers, V.; Bayliss, M.; Castell, J.; Doehmer, J.; Fabre, G.; Fry, J.; Kern, A.; Westmoreland, C. The use of longterm hepatocyte cultures for detecting induction of drug metabolizing enzymes: the current status. ECVAM hepatocyte and metabolically competent systems task force report 1. ALTA, 1999, 27, 579-638.
54. Tang, C.; Prueksaritanont, T.; Use of in vivo animal models to assess pharmacokinetic drug-drug interactions. Pharm. Res., 2010, 27, 1772-1787.
55. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug distribution, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev., 2008, 60, 717-733.
56. Shugarts, S.; Benet, L. Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res., 2009, 26, 2039-2054.
57. Fagerholm, U. The role of permeability in drug ADME/PK, interactions and toxicity-presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharm. Res., 2008, 25, 625-638.
58. Lennernäs, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet., 2003, 42, 1141-1160.
59. Aungst, B. J. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Deliv. Rev., 1999, 39, 105-116.
60. Vermeir, M.; Lachau-Durand, S.; Mannens, G.; Cuyckens, F.; van Hoof, B.; Raoof, A. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with lowdose ritonavir in healthy subjects. Drug Metab. Dispos., 2009, 37, 809-820.
61. Aszalos, A. Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr. Drug Metab., 2008, 9, 1010-1018.
62. Matsuura, H. Saponins in garlic as modifiers of the risk of cardiovascular disease. J. Nutr., 2001, 131, 1000S-1005S.